Pharmaceutical industry executive, Dr Warwick Tong, has been appointed CEO of Cancer Therapeutics CRC Pty Ltd (CTx).
Based in Melbourne, CTx was founded under the CRC program to ensure that novel cancer biology was combined with early drug discovery and development capabilities within Australia.
Dr Tong, who joined CTx in early October, has worked in both the major pharmaceutical and biotechnology sectors for the past 19 years, holding business, commercial and drug development roles.
From 2005, he was Senior Vice President of Development for a Boston-based small molecule drug development company with programs in the cardiovascular, metabolic and oncology areas.
Before that, he worked in a number of roles for Glaxo, GW and GSK in New Zealand, Singapore and the UK, with a focus on business development and commercial strategy.
“Adding commercial value to leading-edge science within Australia will help build critical capabilities in this area of medicine where there are so many patients waiting for new therapies to be developed” Dr Tong said.
“It is a privilege to be leading an organisation that has already demonstrated its ability to discover promising cancer drug candidates.”
Dr Tong assumes the CEO role from Dr Tony Evans, who has moved to the position of Chairman of the CTx Board.
Contact: Dr Warwick Tong Ph: (03) 9345 2143
About CTx: CTx works with cancer researchers to discover and develop their promising cancer targets into pre-clinical small molecule drug candidates.
Partners include Griffith University, The Cancer Council Victoria, St Vincent’s Institute, The Walter and Eliza Hall Institute of Medical Research, CSIRO Materials Science and Engineering, Monash University’s Institute of Pharmaceutical Sciences, Peter MacCallum Cancer Centre, Bionomics Ltd and Cancer Research Technology Ltd (UK).